menu
    • menu

    Company profile for Immunomic Therapeutics

    NEW Drugs in Dev: 6
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax™ fo...
    Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax™ for use in the prevention and treatment of allergic diseases which resulted in over $315M in licensing revenue that year, the company has now focused on the application of its UNITE™ platform in oncology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Immunomic TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    15010 Broschart Road Suite 250 Rockville, MD 20850
    Telephone
    Telephone
    +1.301.968.3501
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immunomix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immunomic-therapeutics-inc-
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/immunomix

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immunomic Therapeutics Receives FDA Clearance For Unite RNA
    Immunomic Therapeutics Receives FDA Clearance For Unite RNA

    20 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260120122000/en/Immunomic-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-a-UNITE-Based-Self-Amplifying-RNA-Vaccine-for-Triple-Negative-Breast-Cancer-to-Be-Studied-Alone-and-in-Combination-with-Keytruda

    BUSINESSWIRE
    20 Jan 2026
    Share Share
    Immunomic Therapeutics to Present RNA Vaccine Data at SITC 2024
    Immunomic Therapeutics to Present RNA Vaccine Data at SITC 2024

    06 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241106799035/en

    BUSINESSWIRE
    06 Nov 2024
    Share Share
    Immunomic Doses First Patient in its Phase 1 Clinical Trial of ITI-1001
    Immunomic Doses First Patient in its Phase 1 Clinical Trial of ITI-1001

    24 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230822556962/en

    BUSINESSWIRE
    24 Aug 2023
    Share Share
    Immunomic Announces Presentation on Manufacturing Cell Therapies at Summit 2023
    Immunomic Announces Presentation on Manufacturing Cell Therapies at Summit 2023

    06 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230306005111/en

    BUSINESSWIRE
    06 Mar 2023
    Share Share
    PharmaJet Partner Immunomic Receive FDA Fast Track Designation for pDNA Vaccine
    PharmaJet Partner Immunomic Receive FDA Fast Track Designation for pDNA Vaccine

    13 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221213005025/en

    BUSINESSWIRE
    13 Dec 2022
    Share Share
    US FDA grants fast track designation to Immunomic Therapeutics’ pDNA vaccine
    US FDA grants fast track designation to Immunomic Therapeutics’ pDNA vaccine

    10 Nov 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=154365&sid=2

    PHARMABIZ
    10 Nov 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search